Mometazon furoat orrspray hatékonyságának vizsgálata. A gyógyszer hazai bevezetését követó elsó pollenszezon gyakorlati tapasztalatai.

Translated title of the contribution: Effectiveness of mometasone furoate nasal spray in seasonal allergic rhinitis. First experiences in practice after the introduction of the drug in Hungary

H. Farkas, Judit Pintér, L. Kalabay, László Jakab, B. Visy, B. Fekete

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: The authors appraised the clinical efficacy of mometasone furoate in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted in 89 patients between 1 July and 15 September 2001. A baseline oto-rhinolaryngological examination was performed. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular, throat and ear clinical signs and general symptoms including cough and dyspnea were characterized using a symptom score. Mometasone furoate was administered intranasally in 100 micrograms doses into both nostrils. Depending on the severity of symptoms, antiallergic eye drops and systemic antihistamines were also allowed. After two weeks of treatment, a follow-up physical examination was performed and the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Mometasone furoate nasal spray alleviated all four nasal symptoms promptly and effectively. In particular, treatment resulted in a 93 percent decrease of overall symptom score. None of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that mometasone furoate nasal spray is a safe and effective intranasal corticosteroid for the therapy of SAR/SARC seasonal allergic rhinitis and rhinoconjunctivitis.

Original languageHungarian
Pages (from-to)1929-1933
Number of pages5
JournalOrvosi Hetilap
Volume143
Issue number33
Publication statusPublished - Aug 18 2002

Fingerprint

Mometasone Furoate
Nasal Sprays
Seasonal Allergic Rhinitis
Hungary
Pharmaceutical Preparations
Sneezing
Therapeutics
Anti-Allergic Agents
Nasal Obstruction
Ophthalmic Solutions
Histamine Antagonists
Pruritus
Pharynx
Nose
Cough
Dyspnea
Signs and Symptoms
Physical Examination
Ear
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mometazon furoat orrspray hatékonyságának vizsgálata. A gyógyszer hazai bevezetését követó elsó pollenszezon gyakorlati tapasztalatai. / Farkas, H.; Pintér, Judit; Kalabay, L.; Jakab, László; Visy, B.; Fekete, B.

In: Orvosi Hetilap, Vol. 143, No. 33, 18.08.2002, p. 1929-1933.

Research output: Contribution to journalArticle

@article{21288888e00e4fff86712478f440d2cc,
title = "Mometazon furoat orrspray hat{\'e}konys{\'a}g{\'a}nak vizsg{\'a}lata. A gy{\'o}gyszer hazai bevezet{\'e}s{\'e}t k{\"o}vet{\'o} els{\'o} pollenszezon gyakorlati tapasztalatai.",
abstract = "INTRODUCTION: The authors appraised the clinical efficacy of mometasone furoate in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted in 89 patients between 1 July and 15 September 2001. A baseline oto-rhinolaryngological examination was performed. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular, throat and ear clinical signs and general symptoms including cough and dyspnea were characterized using a symptom score. Mometasone furoate was administered intranasally in 100 micrograms doses into both nostrils. Depending on the severity of symptoms, antiallergic eye drops and systemic antihistamines were also allowed. After two weeks of treatment, a follow-up physical examination was performed and the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Mometasone furoate nasal spray alleviated all four nasal symptoms promptly and effectively. In particular, treatment resulted in a 93 percent decrease of overall symptom score. None of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that mometasone furoate nasal spray is a safe and effective intranasal corticosteroid for the therapy of SAR/SARC seasonal allergic rhinitis and rhinoconjunctivitis.",
author = "H. Farkas and Judit Pint{\'e}r and L. Kalabay and L{\'a}szl{\'o} Jakab and B. Visy and B. Fekete",
year = "2002",
month = "8",
day = "18",
language = "Hungarian",
volume = "143",
pages = "1929--1933",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - Mometazon furoat orrspray hatékonyságának vizsgálata. A gyógyszer hazai bevezetését követó elsó pollenszezon gyakorlati tapasztalatai.

AU - Farkas, H.

AU - Pintér, Judit

AU - Kalabay, L.

AU - Jakab, László

AU - Visy, B.

AU - Fekete, B.

PY - 2002/8/18

Y1 - 2002/8/18

N2 - INTRODUCTION: The authors appraised the clinical efficacy of mometasone furoate in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted in 89 patients between 1 July and 15 September 2001. A baseline oto-rhinolaryngological examination was performed. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular, throat and ear clinical signs and general symptoms including cough and dyspnea were characterized using a symptom score. Mometasone furoate was administered intranasally in 100 micrograms doses into both nostrils. Depending on the severity of symptoms, antiallergic eye drops and systemic antihistamines were also allowed. After two weeks of treatment, a follow-up physical examination was performed and the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Mometasone furoate nasal spray alleviated all four nasal symptoms promptly and effectively. In particular, treatment resulted in a 93 percent decrease of overall symptom score. None of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that mometasone furoate nasal spray is a safe and effective intranasal corticosteroid for the therapy of SAR/SARC seasonal allergic rhinitis and rhinoconjunctivitis.

AB - INTRODUCTION: The authors appraised the clinical efficacy of mometasone furoate in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted in 89 patients between 1 July and 15 September 2001. A baseline oto-rhinolaryngological examination was performed. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular, throat and ear clinical signs and general symptoms including cough and dyspnea were characterized using a symptom score. Mometasone furoate was administered intranasally in 100 micrograms doses into both nostrils. Depending on the severity of symptoms, antiallergic eye drops and systemic antihistamines were also allowed. After two weeks of treatment, a follow-up physical examination was performed and the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Mometasone furoate nasal spray alleviated all four nasal symptoms promptly and effectively. In particular, treatment resulted in a 93 percent decrease of overall symptom score. None of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that mometasone furoate nasal spray is a safe and effective intranasal corticosteroid for the therapy of SAR/SARC seasonal allergic rhinitis and rhinoconjunctivitis.

UR - http://www.scopus.com/inward/record.url?scp=0037130531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037130531&partnerID=8YFLogxK

M3 - Article

C2 - 12244656

AN - SCOPUS:0037130531

VL - 143

SP - 1929

EP - 1933

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -